Medicus Pharma Publishes Abridged Final Phase II SkinJect^® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Medicus Pharma announced that an abridged Clinical Study Report for SKNJCT-003 has been posted on ClinicalTrials.gov, providing public access to the clinical findings from the completed Phase II study. The study evaluated two dose levels of SkinJect® compared with a device-only microneedle comparator.